Melissa O’Gorman

807 total citations
40 papers, 613 citations indexed

About

Melissa O’Gorman is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Melissa O’Gorman has authored 40 papers receiving a total of 613 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 21 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in Melissa O’Gorman's work include Advanced Breast Cancer Therapies (12 papers), Lung Cancer Treatments and Mutations (11 papers) and Pharmacogenetics and Drug Metabolism (7 papers). Melissa O’Gorman is often cited by papers focused on Advanced Breast Cancer Therapies (12 papers), Lung Cancer Treatments and Mutations (11 papers) and Pharmacogenetics and Drug Metabolism (7 papers). Melissa O’Gorman collaborates with scholars based in United States, Italy and United Kingdom. Melissa O’Gorman's co-authors include Anna Plotka, Akintunde Bello, Weiwei Tan, Huiping Xu, Nicoletta Brega, Vu Le, Karen J. Klamerus, James B. Coutcher, Edward L. Conn and David A. Beebe and has published in prestigious journals such as Cancer Research, The Lancet Oncology and Journal of Medicinal Chemistry.

In The Last Decade

Melissa O’Gorman

40 papers receiving 594 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Melissa O’Gorman United States	15	256	229	220	87	83	40	613
Suoping Zhai United States	16	450 1.8×	173 0.8×	343 1.6×	52 0.6×	66 0.8×	25	969
Georgina Meneses‐Lorente United Kingdom	17	340 1.3×	90 0.4×	260 1.2×	54 0.6×	30 0.4×	51	843
Zahi Mitri United States	15	301 1.2×	254 1.1×	474 2.2×	55 0.6×	20 0.2×	46	903
Alex McCormick United Kingdom	9	260 1.0×	142 0.6×	290 1.3×	70 0.8×	12 0.1×	17	758
Audrey Thomas‐Schoemann France	19	415 1.6×	280 1.2×	550 2.5×	95 1.1×	15 0.2×	54	1.1k
Magdalena Niemira Poland	17	459 1.8×	122 0.5×	121 0.6×	64 0.7×	15 0.2×	47	828
Dirk Trommeshauser Germany	14	254 1.0×	74 0.3×	284 1.3×	36 0.4×	215 2.6×	21	713
You-Ai He United States	7	337 1.3×	226 1.0×	425 1.9×	66 0.8×	37 0.4×	7	895
Gérard Sanderink France	11	243 0.9×	102 0.4×	412 1.9×	31 0.4×	39 0.5×	17	866
Meera Tugnait United States	14	345 1.3×	315 1.4×	308 1.4×	105 1.2×	14 0.2×	25	912

Countries citing papers authored by Melissa O’Gorman

Since Specialization

Citations

This map shows the geographic impact of Melissa O’Gorman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melissa O’Gorman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melissa O’Gorman more than expected).

Fields of papers citing papers by Melissa O’Gorman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melissa O’Gorman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melissa O’Gorman. The network helps show where Melissa O’Gorman may publish in the future.

Co-authorship network of co-authors of Melissa O’Gorman

This figure shows the co-authorship network connecting the top 25 collaborators of Melissa O’Gorman. A scholar is included among the top collaborators of Melissa O’Gorman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melissa O’Gorman. Melissa O’Gorman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, X., Martin E. Dowty, Vu Le, et al.. (2024). Assessment of the Effects of Abrocitinib on the Pharmacokinetics of Probe Substrates of Cytochrome P450 1A2, 2B6 and 2C19 Enzymes and Hormonal Oral Contraceptives in Healthy Individuals. European Journal of Drug Metabolism and Pharmacokinetics. 49(3). 367–381. 3 indexed citations

Chen, Joseph, Alessandra Bearz, Dong‐Wan Kim, et al.. (2023). Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer. Clinical Pharmacokinetics. 63(2). 171–182. 3 indexed citations

Wang, Xiaoxing, Martin E. Dowty, Svitlana Tatulych, et al.. (2022). Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals. European Journal of Drug Metabolism and Pharmacokinetics. 47(3). 419–429. 22 indexed citations

Chen, Joseph, et al.. (2021). Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study. Clinical Pharmacokinetics. 60(10). 1313–1324. 21 indexed citations

O’Gorman, Melissa, et al.. (2021). Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants. Cancer Chemotherapy and Pharmacology. 89(1). 71–81. 6 indexed citations

Yu, Yanke, Justin Hoffman, Anna Plotka, et al.. (2020). Palbociclib (PD-0332991) pharmacokinetics in subjects with impaired renal function. Cancer Chemotherapy and Pharmacology. 86(6). 701–710. 10 indexed citations

Chen, Joseph, Alessandra Bearz, D. Kim, et al.. (2019). P1.01-84 Interaction of Lorlatinib with CYP2B6, CYP2C9, UGT, and P-gp Probe Drugs in Patients with Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S392–S393. 2 indexed citations

Patel, Maulik, et al.. (2019). The effect of itraconazole on the pharmacokinetics of lorlatinib: results of a phase I, open-label, crossover study in healthy participants. Investigational New Drugs. 38(1). 131–139. 17 indexed citations

El-Khoueiry, Anthony B., John Sarantopoulos, Cindy L. O’Bryant, et al.. (2018). Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 81(4). 659–670. 16 indexed citations

10.

Ruiz-Garcı́a, Ana, Anna Plotka, Melissa O’Gorman, & Diane D. Wang. (2017). Effect of food on the bioavailability of palbociclib. Cancer Chemotherapy and Pharmacology. 79(3). 527–533. 27 indexed citations

11.

Sahasrabudhe, Vaishali, Steven G. Terra, Didier Saur, et al.. (2017). The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus. The Journal of Clinical Pharmacology. 57(11). 1432–1443. 42 indexed citations

12.

Tan, Weiwei, Shinji Yamazaki, Theodore R. Johnson, et al.. (2016). Effects of Renal Function on Crizotinib Pharmacokinetics: Dose Recommendations for Patients with ALK-Positive Non-Small Cell Lung Cancer. Clinical Drug Investigation. 37(4). 363–373. 16 indexed citations

13.

Xu, Huiping, Melissa O’Gorman, Weiwei Tan, Nicoletta Brega, & Akintunde Bello. (2015). The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects. European Journal of Clinical Pharmacology. 71(12). 1441–1449. 26 indexed citations

14.

Xu, Huiping, et al.. (2014). Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects. The Journal of Clinical Pharmacology. 55(1). 104–113. 36 indexed citations

15.

Johnson, Theodore R., Weiwei Tan, Lance Goulet, et al.. (2014). Metabolism, excretion and pharmacokinetics of [¹⁴C]crizotinib following oral administration to healthy subjects. Xenobiotica. 45(1). 45–59. 45 indexed citations

16.

Hoffman, Justin, et al.. (2014). A Phase 1 Open-Label Fixed-Sequence Two-Period Crossover Study of the Effect of Multiple Doses of Tamoxifen on Palbociclib (PD-0332991) Pharmacokinetics in Healthy Male Volunteers. Annals of Oncology. 25. i25–i25. 3 indexed citations

17.

O’Gorman, Melissa, et al.. (2013). Bioequivalence of fixed-dose combination Myrin®-P Forte and reference drugs in loose combination. The International Journal of Tuberculosis and Lung Disease. 17(12). 1596–1601. 3 indexed citations

18.

Gao, Xiang, Melissa O’Gorman, Jack Cook, Haihong Shi, & Robert R. LaBadie. (2012). A Randomized, Open‐Label, 3‐Way Crossover Study to Demonstrate Bioequivalence of Sildenafil Powder for Oral Suspension With Tablets Used Commercially and in Clinical Studies for the Treatment of Pulmonary Arterial Hypertension. Clinical Pharmacology in Drug Development. 1(4). 152–157. 4 indexed citations

19.

Zhao, Qinying, Elias Schwam, Terence Fullerton, Melissa O’Gorman, & Aaron H. Burstein. (2010). Pharmacokinetics, Safety, and Tolerability Following Multiple Oral Doses of Varenicline Under Various Titration Schedules in Elderly Nonsmokers. The Journal of Clinical Pharmacology. 51(4). 492–501. 8 indexed citations

20.

Burstein, Aaron H., David J. Clark, Melissa O’Gorman, et al.. (2007). Lack of Pharmacokinetic and Pharmacodynamic Interactions Between a Smoking Cessation Therapy, Varenicline, and Warfarin: An In Vivo and In Vitro Study¹. The Journal of Clinical Pharmacology. 47(11). 1421–1429. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact